173 related articles for article (PubMed ID: 24891233)
1. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
[TBL] [Abstract][Full Text] [Related]
2. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
5. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
[No Abstract] [Full Text] [Related]
6. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
Kim SH; Kim IH; Kim SW; Lee SO
World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
[TBL] [Abstract][Full Text] [Related]
7. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
8. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Matsumoto K; Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
10. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
11. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
Inaba Y; Arai Y; Yamaura H; Sato Y; Najima M; Aramaki T; Sone M; Kumada T; Tanigawa N; Anai H; Yoshioka T; Ikeda M;
Am J Clin Oncol; 2011 Feb; 34(1):58-62. PubMed ID: 20177362
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
13. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
[TBL] [Abstract][Full Text] [Related]
14. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
16. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
17. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
19. Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes.
Wehbe H; Henson R; Lang M; Meng F; Patel T
J Pharmacol Exp Ther; 2006 Dec; 319(3):1153-61. PubMed ID: 16982703
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
